Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant - Related Studies

Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant

This study is currently recruiting participants.

Study NCT00082706. Last updated on October 22, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Bladder Cancer
		Urethral Cancer

2	Additional conditions recognized in this trial
		Adenocarcinoma
		Urethral Neoplasms
		Urinary Bladder Neoplasms

3	More general conditions related to this trial
		Carcinoma
		Neoplasms
		Neoplasms by Histologic Type
		Neoplasms by Site
		Neoplasms, Glandular and Epithelial
		Urethral Diseases
		Urinary Bladder Diseases
		Urogenital Neoplasms
		Urologic Diseases
		Urologic Neoplasms

4	Interventions listed in this trial
		cisplatin
		fluorouracil
		gemcitabine hydrochloride
		leucovorin calcium

5	Additional drug interventions recognized in this trial
		Gemcitabine
		Leucovorin

6	More general drug interventions related to this trial
		Anti-Infective Agents
		Antimetabolites
		Antimetabolites, Antineoplastic
		Antineoplastic Agents
		Antiviral Agents
		Enzyme Inhibitors
		Growth Substances
		Immunologic Factors
		Immunosuppressive Agents
		Micronutrients
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Physiological Effects of Drugs
		Radiation-Sensitizing Agents
		Therapeutic Uses
		Vitamin B Complex
		Vitamins

7	Sponsors listed in this trial
		M.D. Anderson Cancer Center
		National Cancer Institute (NCI)